Clinical Daily Summary
Clinical Daily Summary: What Happened on October 4, 2026
AstraZeneca’s tozorakimab cut COPD flare-ups by 29% to 34% in two Phase 3 trials
The studies enrolled 2,306 patients. A combined analysis found larger reductions among patients with higher blood eosinophil levels.
Today in brief
In OBERON and TITANIA, former smokers taking tozorakimab had 29% and 34% fewer moderate-to-severe COPD exacerbations, respectively, than those taking placebo.1
Tozorakimab lowered COPD exacerbations in OBERON and TITANIA
The double-blind, placebo-controlled trials enrolled 2,306 symptomatic patients with a recent history of multiple moderate or at least one severe COPD exacerbation.1 Patients received 300 mg of tozorakimab or placebo every four weeks for 52 weeks, alongside their usual inhaled maintenance treatment.1
Across current and former smokers, exacerbation rates fell 30% in OBERON and 29% in TITANIA compared with placebo.1 In a combined analysis, rates fell 43% among patients with blood eosinophil counts of at least 300 cells per microliter, versus 23% among those with counts below 150 cells per microliter.1 The analysis using the 150-cells-per-microliter threshold was conducted after the trials were designed.1
AstraZeneca says tozorakimab is designed to block interleukin-33 signaling and address inflammation and mucus dysfunction.1 Tozorakimab is also being tested for severe viral lower respiratory tract disease in a Phase 3 study and for asthma in a Phase 2 study.1 The FDA granted tozorakimab Fast Track status for COPD and severe viral lower respiratory tract disease.1